Percutaneous liver tumor ablation techniques are well-established and effective therapeutic alternatives for the treatment of primary and secondary liver tumors. Hepatocellular carcinoma (HCC) and colorectal oligometastatic disease are the most common indications. There are specific indications and contraindications, but the techniques are mostly limited to small oligonodular and favourably-located lesions.
They potentially include both thermal (radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation) and non-thermal ablation methods (irreversible electroporation (IRE)) 6.
On this page:
Indications
-
HCC: the Barcelona clinic liver cancer (BCLC) group recommendations 3 have been widely adopted for HCC treatment decision and percutaneous ablation is recommended, as an alternative to surgery, for:
stage 0 (performance status 0 and Child-Pugh score A) - very early stage: single liver lesion measuring <2 cm
stage A (performance status 0-2 and Child-Pugh score A-C) - early stage: solitary lesion >2 cm or early multifocal disease characterized by up to 3 lesions measuring less than 3 cm
-
liver metastasis: when a patient is not a candidate for surgical resection or has failed other therapies 2. As per an international consensus in 2015 4
lesion size: <3 cm, but with allowance to <5 cm well-located lesions (defined as those with easy access)
number of lesions: five or fewer tumors should routinely be considered for ablation. The consensus opens margins to up to nine lesions in selected cases
-
benign liver lesions: selected application of percutaneous ablation for the treatment of benign liver lesions (e.g. hemangiomas and hepatic adenomas) has been performed 1
prevent hemorrhage
potential malignant degeneration (adenomas)
Contraindications
-
general
uncorrectable bleeding diathesis (abnormal coagulation indices)
active infection
poor patient performance status (ECOG >3)
Child-Pugh score C
-
radiofrequency ablation (RFA) / microwave ablation (MWA)
tumor involving major hepatic bile ducts
proximity to vital structures such as a major vessel or adjacent organs (e.g. colon) - relative contraindication
Procedure
Preprocedural evaluation
recent CT or MRI liver is required for planning
-
challenging locations not necessarily preclude the procedure
at the hepatic dome abutting the diaphragm
-
close to the hepatic hilum
potential risk of damaging major bile ducts or central vessels
-
at a subcapsular location
pain at the liver capsule
no evidence supporting antibiotic prophylaxis
Technique
-
sedation
general anesthesia is not mandatory
anesthesiology care is advised
-
artificial ascites or fluid dissection
RFA: dextrose 5% is preferred with saline contraindicated
MWA: any type of fluid
gas dissection with CO2 is an alternative to fluid
Postprocedural care
-
imaging follow-up to assess treatment success is recommended with either multiphase CT liver or MRI liver
-
the first scan one month after treatment
most perfusion abnormalities tend to vanish within a month of the procedure 4
note that faint enhancement surrounding the ablation zone may be seen and is related to treatment-induced inflammatory reaction and granulation tissue. They tend to vanish within 6 months after treatment 4
eventual gas bubbles related to necrotic tumor tend to disappear within several days
then three months intervals
-
Complications
-
reported post-ablation self-limiting symptoms include
nausea and vomiting
loss of appetite
fever
abdominal pain
-
post-procedural complications include
liver abscess
bowel perforation
pneumothorax
intraperitoneal bleeding
procedural mortality is low
Outcomes
incomplete ablation: the presence of residual tumor post-treatment, usually picked on the first imaging follow-up
-
complete ablation
HCC: non-vascular ablation zone on the follow-up scan
metastasis: non-vascular ablation zone covering the target with a good surrounding margin